

EP 15 196 240.4 / 3056568

Patentee: Chugai Seiyaku Kabushiki Kaisha

Opposition by: Strawman Limited; Novo Nordisk A/S

Vossius Ref.: P3148 OPP(EP/1) S3

AUXILIARY REQUEST 3

1. A method for producing a modified humanized, chimeric or human IgG antibody comprising an FcRn-binding domain, having prolonged or reduced half-life in blood as compared to before said modification, wherein the method comprises:
 - (a) modifying a nucleic acid encoding a humanized, chimeric or human IgG antibody to change the charge of at least one amino acid residue that is exposed on the surface of the antibody, wherein said at least one amino acid residue is an amino acid residue in a heavy chain or light chain variable region of said antibody, and wherein the change in charge of said at least one amino acid residue is achieved by amino acid substitution;
 - (b) culturing a host cell to express the nucleic acid;
 - (c) collecting said modified antibody from the host cell culture; and
 - (d) assessing whether said half-life has been prolonged or reduced by conducting kinetic tests.

2. A method for prolonging or reducing the half-life in blood of a humanized, chimeric or human IgG antibody comprising an FcRn-binding domain, which method comprises changing the charge of at least one amino acid residue that is exposed on the surface of the antibody, wherein the amino acid residue whose charge is changed is an amino acid residue in a heavy chain or light chain variable region of said antibody, and wherein the change of charge of the amino acid residue is achieved by an amino acid substitution, and which method further comprises assessing whether said half-life has been prolonged or reduced as compared to before said substitution by conducting kinetic tests.